Published in N Engl J Med on October 05, 2006
Study for Recalcitrant Age Related Macular Degeneration (TURF) | NCT01543568
Proton Radiation Therapy for Macular Degeneration | NCT01833325
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab | NCT01810042
MMP-9 Inhibition for Recalcitrant Wet AMD | NCT04504123
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy (VAULT) | NCT01950741
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol (2014) 4.34
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 3.85
Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med (2008) 3.67
A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology (2007) 3.49
Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS One (2008) 3.46
Age-related macular degeneration. Lancet (2008) 3.34
Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care (2010) 3.29
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol (2007) 3.08
Comparison of natamycin and voriconazole for the treatment of fungal keratitis. Arch Ophthalmol (2010) 2.98
Vascular endothelial growth factor in eye disease. Prog Retin Eye Res (2008) 2.73
Mechanisms of age-related macular degeneration. Neuron (2012) 2.62
Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond) (2012) 2.52
CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature (2009) 2.39
Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol (2010) 2.32
Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res (2010) 2.30
One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol (2014) 2.24
Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology (2012) 2.19
Immunology of age-related macular degeneration. Nat Rev Immunol (2013) 2.14
Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov (2010) 2.14
The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med (2006) 2.12
Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27~24 clusters. Proc Natl Acad Sci U S A (2011) 2.10
Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc (2009) 2.09
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) (2011) 2.05
A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 2.04
Bimonthly injections of ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2014) 2.04
Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol (2013) 1.97
A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2008) 1.89
MicroRNAs regulate ocular neovascularization. Mol Ther (2008) 1.89
Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol (2007) 1.88
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.76
Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.70
New treatments for neovascular acute macular degeneration. BMJ (2007) 1.69
Ocular neovascularization. J Mol Med (Berl) (2013) 1.65
Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol (2013) 1.61
Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2009) 1.57
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.57
Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol (2007) 1.55
[Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application]. Ophthalmologe (2007) 1.53
Hypoxia-induced angiogenesis: good and evil. Genes Cancer (2011) 1.52
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov (2012) 1.52
Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr (2011) 1.50
Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond) (2013) 1.49
Roles for VEGF in the adult. Microvasc Res (2007) 1.48
Colour photographs for screening in neovascular age-related macular degeneration: are they necessary? Eye (Lond) (2011) 1.47
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc (2012) 1.46
Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ (2007) 1.46
Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2014) 1.45
Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med (2010) 1.45
A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization. Invest Ophthalmol Vis Sci (2014) 1.43
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol (2014) 1.42
Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes. Clin Ophthalmol (2016) 1.42
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol (2014) 1.41
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol (2014) 1.41
Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. PLoS One (2015) 1.40
Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol (2006) 1.39
Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J (2012) 1.38
A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One (2012) 1.38
Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol (2008) 1.37
Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy. Eye (Lond) (2016) 1.37
Ultrahigh-speed swept-source OCT angiography in exudative AMD. Ophthalmic Surg Lasers Imaging Retina (2014) 1.35
CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS One (2009) 1.34
Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 1.34
Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 1.33
Attenuated glial reactions and photoreceptor degeneration after retinal detachment in mice deficient in glial fibrillary acidic protein and vimentin. Invest Ophthalmol Vis Sci (2007) 1.33
Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J (2010) 1.31
Oxidative stress promotes ocular neovascularization. J Cell Physiol (2009) 1.28
Mitochondrial DNA damage as a potential mechanism for age-related macular degeneration. Invest Ophthalmol Vis Sci (2010) 1.28
Screening and Treatment in Retinopathy of Prematurity. Dtsch Arztebl Int (2015) 1.26
Age-related macular degeneration: genetic and environmental factors of disease. Mol Interv (2010) 1.24
Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol (2013) 1.23
A very effective treatment for neovascular macular degeneration. N Engl J Med (2006) 1.23
Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther (2010) 1.22
Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol (2010) 1.21
Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol (2014) 1.20
Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol (2008) 1.20
Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol (2014) 1.20
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2008) 1.17
Anti-VEGF Treatment Strategies for Wet AMD. J Ophthalmol (2012) 1.17
Prevalence of ocular fundus pathology in patients with chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.17
Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2010) 1.17
Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res (2014) 1.17
Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol (2013) 1.16
Lasting controversy on ranibizumab and bevacizumab. Theranostics (2011) 1.15
The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary. Eye (Lond) (2013) 1.15
Biotech in a blink. Nat Biotechnol (2010) 1.13
Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model. Invest Ophthalmol Vis Sci (2011) 1.12
Nutritional supplements for age-related macular degeneration. Curr Opin Ophthalmol (2010) 1.12
Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol (2007) 1.12
Structure-function correlation of the human central retina. PLoS One (2010) 1.12
Drug-induced uveitis. J Ophthalmic Inflamm Infect (2013) 1.11
Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm (2010) 1.11
Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care. Eye (Lond) (2012) 1.11
Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol (2010) 1.09
Optical Coherence Tomography Angiography of Asymptomatic Neovascularization in Intermediate Age-Related Macular Degeneration. Ophthalmology (2016) 1.09
Modelling the genetic risk in age-related macular degeneration. PLoS One (2012) 1.09
Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks. Eye (Lond) (2012) 1.08
Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. Invest Ophthalmol Vis Sci (2013) 1.07
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology (2009) 6.44
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol (2008) 5.22
Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol (2003) 4.78
Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology (2010) 4.09
A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology (2009) 3.76
Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol (2007) 3.00
A recombineering pipeline for functional genomics applied to Caenorhabditis elegans. Nat Methods (2006) 2.87
Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol (2006) 2.82
Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina (2008) 2.72
Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis. Retina (2013) 2.49
Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol (2013) 2.44
The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology (2013) 2.35
Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology (2012) 2.32
Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol (2012) 2.30
Evaluation of wound closure in oblique 23-gauge sutureless sclerotomies with visante optical coherence tomography. Am J Ophthalmol (2008) 2.26
A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology (2006) 2.17
Utility of intraoperative optical coherence tomography during vitrectomy surgery for vitreomacular traction syndrome. Retina (2014) 2.15
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol (2013) 2.14
Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology (2013) 2.13
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology (2006) 2.07
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol (2006) 2.04
Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol (2005) 1.99
Intrasurgical dynamics of macular hole surgery: an assessment of surgery-induced ultrastructural alterations with intraoperative optical coherence tomography. Retina (2014) 1.97
Novel microarchitectural dynamics in rhegmatogenous retinal detachments identified with intraoperative optical coherence tomography. Retina (2013) 1.96
Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore) (2003) 1.94
Optical coherence tomography enhanced depth imaging of choroidal tumors. Am J Ophthalmol (2011) 1.91
Short-term outcomes of 23-gauge pars plana vitrectomy. Am J Ophthalmol (2008) 1.89
Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol (2013) 1.86
Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology (2009) 1.86
Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol (2003) 1.74
Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina (2007) 1.68
Panretinal photocoagulation for proliferative diabetic retinopathy: pattern scan laser versus argon laser. Am J Ophthalmol (2011) 1.62
Optical coherence tomography 3: Automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci (2004) 1.62
Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol (2006) 1.62
Indocyanine green staining of anteriorly placed zonules. J Cataract Refract Surg (2003) 1.61
Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology (2008) 1.60
Solitary fibrous tumor of the orbit: is it rare? Report of a case series and review of the literature. Ophthalmology (2003) 1.58
Adult-onset foveomacular vitelliform dystrophy: a study by optical coherence tomography. Am J Ophthalmol (2003) 1.56
Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology (2009) 1.52
Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol (2007) 1.51
Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.47
Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology (2007) 1.45
Prevalence of outer retinal tubulation after anti-VEGF therapy for age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina (2015) 1.42
Surgeon Willingness to Participate in Randomized Controlled Trials for the Treatment of Femoroacetabular Impingement. Arthroscopy (2015) 1.39
Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging (2005) 1.38
Neovascular age-related macular degeneration: potential therapies. Drugs (2008) 1.38
Activity Level and Severity of Dysplasia Predict Age at Bernese Periacetabular Osteotomy for Symptomatic Hip Dysplasia. J Bone Joint Surg Am (2016) 1.38
Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology (2006) 1.37
Descriptive epidemiology of femoroacetabular impingement: a North American cohort of patients undergoing surgery. Am J Sports Med (2013) 1.36
Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol (2005) 1.33
Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol (2012) 1.31
Intravitreal ranibizumab for choroidal neovascularization in angioid streaks. Am J Ophthalmol (2010) 1.30
Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. Am J Clin Nutr (2008) 1.29
IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys (2004) 1.26
Sunlight exposure, antioxidants, and age-related macular degeneration. Arch Ophthalmol (2008) 1.21
Variations in apolipoprotein E frequency with age in a pooled analysis of a large group of older people. Am J Epidemiol (2011) 1.19
Epstein-Barr virus-related bilateral acute retinal necrosis in a patient with X-linked lymphoproliferative disorder. Arch Ophthalmol (2003) 1.19
Visualizing vitreous using Kenalog suspension. J Cataract Refract Surg (2003) 1.19
Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology (2011) 1.18
Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies. Hum Mutat (2011) 1.17
Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results. Ophthalmology (2006) 1.17
Evaluation of choroidal thickness in retinitis pigmentosa using enhanced depth imaging optical coherence tomography. Br J Ophthalmol (2012) 1.17
Visual impairment and quality of life in the older European population, the EUREYE study. Acta Ophthalmol (2009) 1.14
A novel segmentation algorithm for volumetric analysis of macular hole boundaries identified with optical coherence tomography. Invest Ophthalmol Vis Sci (2013) 1.13
Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmol (2010) 1.12
Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. Int J Epidemiol (2012) 1.12
A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology (2010) 1.10
Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study. Ophthalmology (2012) 1.09
Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am J Ophthalmol (2006) 1.09
Contrast-enhanced intraoperative optical coherence tomography. Br J Ophthalmol (2013) 1.06
Blast eye injuries: a review for first responders. Disaster Med Public Health Prep (2010) 1.06
Macular hole following intravitreal ranibizumab injection for choroidal neovascular membrane caused by age-related macular degeneration. Acta Ophthalmol (2009) 1.06
Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina (2010) 1.05
Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiol (2004) 1.05
Comparison of retinal thickness measurements between three-dimensional and radial scans on spectral-domain optical coherence tomography. Am J Ophthalmol (2009) 1.05
Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study. Br J Ophthalmol (2006) 1.05
High-resolution spectral domain optical coherence tomography findings in multifocal vitelliform macular dystrophy. Surv Ophthalmol (2009) 1.04
Do plain radiographs correlate with CT for imaging of cam-type femoroacetabular impingement? Clin Orthop Relat Res (2012) 1.03
Pathologic insights from integrated imaging of reticular pseudodrusen in age-related macular degeneration. Retina (2011) 1.03
Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis. Ophthalmology (2011) 1.02
Reopening of previously closed macular holes after cataract extraction. Am J Ophthalmol (2007) 1.02
Optical coherent tomography features of malattia leventinese. Am J Ophthalmol (2006) 1.01
VESGEN 2D: automated, user-interactive software for quantification and mapping of angiogenic and lymphangiogenic trees and networks. Anat Rec (Hoboken) (2009) 1.01
Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol (2002) 1.00
Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis. Retina (2008) 0.98
Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology (2005) 0.98
Stereotactic low-voltage x-ray irradiation for age-related macular degeneration. Br J Ophthalmol (2010) 0.98
Comparing retinal thickness measurements using automated fast macular thickness map versus six-radial line scans with manual measurements. Ophthalmology (2009) 0.98
Evaluation of wound closure using different incision techniques with 23-gauge and 25-gauge microincision vitrectomy systems. Retina (2008) 0.97
Selective inhibition of angiogenesis in small blood vessels and decrease in vessel diameter throughout the vascular tree by triamcinolone acetonide. Invest Ophthalmol Vis Sci (2008) 0.97